Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 104

1.

Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.

Guarnera C, Bramanti P, Mazzon E.

Drug Des Devel Ther. 2017 Jul 28;11:2193-2207. doi: 10.2147/DDDT.S137572. eCollection 2017. Review.

PMID:
28814828
2.

Multiple Sclerosis: Immunopathology and Treatment Update.

Dargahi N, Katsara M, Tselios T, Androutsou ME, de Courten M, Matsoukas J, Apostolopoulos V.

Brain Sci. 2017 Jul 7;7(7). pii: E78. doi: 10.3390/brainsci7070078. Review.

3.

Mechanism of action of three newly registered drugs for multiple sclerosis treatment.

Kasarełło K, Cudnoch-Jędrzejewska A, Członkowski A, Mirowska-Guzel D.

Pharmacol Rep. 2017 Aug;69(4):702-708. doi: 10.1016/j.pharep.2017.02.017. Epub 2017 Feb 22. Review.

PMID:
28550802
4.

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.

Cochrane Database Syst Rev. 2017 Apr 25;4:CD012200. doi: 10.1002/14651858.CD012200.pub2. Review.

PMID:
28440858
5.

What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.

Pistono C, Osera C, Boiocchi C, Mallucci G, Cuccia M, Bergamaschi R, Pascale A.

Pharmacol Res. 2017 Jun;120:279-293. doi: 10.1016/j.phrs.2017.03.025. Epub 2017 Apr 8. Review.

PMID:
28396093
6.

Classifying PML risk with disease modifying therapies.

Berger JR.

Mult Scler Relat Disord. 2017 Feb;12:59-63. doi: 10.1016/j.msard.2017.01.006. Epub 2017 Jan 6. Review.

PMID:
28283109
7.

Clinical Pharmacokinetic Monitoring of Leflunomide in Renal Transplant Recipients with BK Virus Reactivation: A Review of the Literature.

Ng JC, Leung M, Wright AJ, Ensom MH.

Clin Pharmacokinet. 2017 Feb 28. doi: 10.1007/s40262-017-0521-9. [Epub ahead of print] Review.

PMID:
28247238
8.

Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks.

Alroughani R, Altintas A, Al Jumah M, Sahraian M, Alsharoqi I, AlTahan A, Daif A, Dahdaleh M, Deleu D, Fernandez O, Grigoriadis N, Inshasi J, Karabudak R, Taha K, Totolyan N, Yamout BI, Zakaria M, Bohlega S.

Mult Scler Int. 2016;2016:1034912. doi: 10.1155/2016/1034912. Epub 2016 Dec 18. Review.

9.

Teriflunomide -- Benefit Assessment According to §35a Social Code Book V [Internet].

Institute for Quality and Efficiency in Health Care.

Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2013 Dec 20.

10.

Safety concerns and risk management of multiple sclerosis therapies.

Soelberg Sorensen P.

Acta Neurol Scand. 2017 Sep;136(3):168-186. doi: 10.1111/ane.12712. Epub 2016 Nov 27. Review.

PMID:
27891572
11.

NF-κB Pathways in the Pathogenesis of Multiple Sclerosis and the Therapeutic Implications.

Leibowitz SM, Yan J.

Front Mol Neurosci. 2016 Sep 15;9:84. eCollection 2016. Review.

12.

Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.

Fogarty E, Schmitz S, Tubridy N, Walsh C, Barry M.

Mult Scler Relat Disord. 2016 Sep;9:23-30. doi: 10.1016/j.msard.2016.06.001. Epub 2016 Jun 8. Review.

PMID:
27645339
13.

Multiple Sclerosis in Pediatrics: Current Concepts and Treatment Options.

Jancic J, Nikolic B, Ivancevic N, Djuric V, Zaletel I, Stevanovic D, Peric S, van den Anker JN, Samardzic J.

Neurol Ther. 2016 Dec;5(2):131-143. Epub 2016 Sep 17. Review.

14.

Disease modifying therapies for relapsing multiple sclerosis.

Wingerchuk DM, Weinshenker BG.

BMJ. 2016 Aug 22;354:i3518. doi: 10.1136/bmj.i3518. Review.

PMID:
27549763
16.

The efficacy and safety of teriflunomide based therapy in patients with relapsing multiple sclerosis: A meta-analysis of randomized controlled trials.

Xu M, Lu X, Fang J, Zhu X, Wang J.

J Clin Neurosci. 2016 Nov;33:28-31. doi: 10.1016/j.jocn.2016.02.041. Epub 2016 Aug 1. Review.

PMID:
27492048
17.

Use of Disease-Modifying Therapies in Pediatric MS.

Simone M, Chitnis T.

Curr Treat Options Neurol. 2016 Aug;18(8):36. doi: 10.1007/s11940-016-0420-7. Review.

PMID:
27314428
18.

Immunological treatment of multiple sclerosis.

Diebold M, Derfuss T.

Semin Hematol. 2016 Apr;53 Suppl 1:S54-7. doi: 10.1053/j.seminhematol.2016.04.016. Epub 2016 Apr 7. Review.

PMID:
27312167
20.

Management of multiple sclerosis and the integration of related specialty pharmacy programs within health systems.

Habibi M, Kuttab HM.

Am J Health Syst Pharm. 2016 Jun 1;73(11):811-9. doi: 10.2146/ajhp150723. Epub 2016 Apr 28. Review.

PMID:
27126827

Supplemental Content

Loading ...
Support Center